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Available online 12 February 2016Background: Rheumatic heart disease (RHD) and HIV are prevalent diseases in sub-Saharan Africa, but little is
known about their potential interrelationships. The objective of this study was to assess the prevalence of
protective natural autoantibodies among patients with RHD in Uganda, and to determine whether the levels of
these autoantibodies are affected by HIV status.
Methods: Participants were grouped according to RHD and HIV status. The three control groups (RHD−HIV−,
RHD−HIV+, RHD+HIV−) were age-matched to the RHD+HIV+ participants. All participants underwent
HIV testing and echocardiography to evaluate for RHD. Natural autoantibody levels reactivewith phosphorylcholine
(PC) and malondialdehyde (MDA) were measured.
Findings:We enrolled 220 participants; 21 with both RHD and HIV. Ages ranged from 10 to 60 years, with female
predominance (144/220, 65%). After adjusting for age and gender, HIV infection and RHD were each associated
with low IgM anti-PC (HIV: p b 0.0001 and RHD: p = 0.01). A distinct HIV∗RHD interaction was identiﬁed (p =
0.045) with increased IgG anti-MDA levels in HIV infected subjects without RHD, whereas IgG anti-MDA levels
were decreased in HIV infected subjects with RHD.
Interpretation: We found that HIV and RHD are associated with alterations in natural autoantibody responses
previously linked to an increased risk for atherosclerosis and autoimmune inﬂammatory disease.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionRheumatic heart disease (RHD) and HIV are prevalent in Uganda and
other sub-Saharan African countries. Rheumatic heart disease (RHD)
affects 15million people worldwidewith an estimated 1.4million deaths
annually. In Uganda RHD is the most common cause of heart disease
within the 15 to 49 age group (Remenyi et al., 2012; Okello et al., 2012;
Marijan et al., 2012; Sliwa and Zilla, 2012). The immunopathogenesis ofMedical Scholars Program, the
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. This is an open access article underchronic valvular inﬂammation in RHD including the role of cellular vs.
humoral immune responses, and the identity of the responsible
immunodominant epitopes that drive the progression of disease are de-
bated (Tandon et al., 2013). HIV currently affects 5–10% of Ugandan
adults, which is improved from nearly 30% in the early 1990s (The
Republic of Uganda, 2014). The immune deﬁciency and dysfunction
caused by HIV and AIDS has been shown to impact susceptibility to and
progression of other autoimmune diseases (Zandman-Goddard and
Shoenfeld, 2002); however, the impact of HIV infection on RHD patho-
genesis has not been investigated.
Natural arising autoantibodies to oxidation-associated epitopes have
been shown to modulate the initiation and progression of a range of
immune-mediated inﬂammatory diseases including atherosclerosis.
These autoantibodies are postulated to play roles in homeostasis and
immune regulation (Gronwall and Silverman, 2014), and altered
serum levels correlate with certain disease states. IgM natural autoanti-
bodies reactive with the phosphorylcholine (PC) head group are com-
monly cross-reactive with PC determinants on oxidatively modiﬁedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
162 D.M. Huck et al. / EBioMedicine 5 (2016) 161–166low density lipoprotein (LDL), and apoptotic cells but not with healthy
cells. In mice and humans, the antibody genes for dominant B-cell
clones to PC determinants show evidence of clonal restriction and con-
vergent somatic evolution (Silverman, 2015). Malondialdehyde (MDA)
is a small chemically reactive compound that readily forms adducts on
proteins, and IgM anti-MDA antibodies are common at birth and show
great structural and clonal diversity (Chou et al., 2009; Unpublished
data). Induction of high levels of IgM anti-PC antibodies has been
shown to protect hyperlipidemic mice from atherosclerosis (Binder
et al., 2003), and low IgM anti-PC correlates with increased risk for
stroke and myocardial infarction in population-based cohort studies
(Fiskesund et al., 2010; Gronlund et al., 2009). These natural autoan-
tibodies may also modulate the pathogenesis of experimental and
clinical autoimmune disease. IgM antibodies to PC enhance the clear-
ance of damaged and apoptotic cells by binding to oxidation-
associated epitopes, enhancing recruitment of C1q and mannose
binding lectin and suppressing Toll-like receptor mediated inﬂam-
matory responses (Chen et al., 2009a; Chen et al., 2009b; Vas et al.,
2012). In systemic lupus erythematous (SLE) patients, higher levels
of anti-PC IgM have been associated with lower clinical disease activ-
ity, lower rates of MI and stroke, as well as reduced preclinical ath-
erosclerosis burden based on carotid ultrasound (Gronwall et al.,
2012; Gronwall et al., 2014).
Due to the common expression of these natural autoantibodies, we
postulated that theremay be similar roles in resolution of cellular injury
in damaged valvular tissues in RHD, yet this has not previously been
studied. In theory, high IgM anti-PC antibody titers would be predicted
to promote rapid clearance of apoptotic cells in damaged tissues,
suppressing over-exuberant inﬂammatory responses and release of
autoantigens from cells, which may also have direct or indirect inﬂu-
ence on recruitment and activation of auto-reactive lymphocytes.
Given their putative role(s) in inﬂammatory vascular conditions, pro-
tective natural autoantibodies may also affect the risk of atherosclerosis
in patientswithRHDandHIV. The chronic systemic inﬂammation that is
a hallmark of RHD and rheumatic fever may contribute to increased
risk of atherosclerosis (Habeeb and Hadidi, 2011; Zoller et al.,
2012). HIV infection is a well-known risk factor for accelerated ath-
erosclerosis independent of use of antiretroviral therapy (ART), due
to chronic inﬂammation and immune activation (Longenecker and
Triant, 2014). In a recent study, HIV infection was associated with
lower protective IgM natural autoantibodies and higher levels of
IgG natural autoantibodies against oxidized forms of LDL (Yilmaz
et al., 2014) but the relevance to clinical cardiovascular disease
was not examined (Tsimikas et al., 2007). Perturbations in the
levels of these natural autoantibodies may therefore contribute to
the accelerated atherosclerosis seen in HIV.
The purpose of the current study was to assess the relative preva-
lence of these natural autoantibodies among patients with and without
RHD inUganda and to determinewhether the presence of these autoan-
tibodies may be impacted by HIV infection. We sought to test the hy-
pothesis that both conditions would be associated with reduced levels
of oxidation-associated IgM anti-PC natural autoantibodies along with
increased IgG anti-MDA antibodies.
2. Methods
2.1. Study Participants and Enrollment
Study participants were enrolled from the Joint Clinical Research
Centre and the Uganda Heart Institute in Kampala, Uganda from April
to June 2014. For this cross-sectional study, we recruited subjects that
were then stratiﬁed by RHD and HIV status into groups (RHD−HIV−,
RHD−HIV+, RHD+HIV−) that were age-matched to the RHD+
HIV+ group. All participants were N8 years old and had a transthoracic
echocardiogram performed for valvular heart disease, due to clinical pre-
sentation or as part of a screening protocol.We included thosewith overtclinical RHD or deﬁnite latent RHD, as deﬁned byWorld Heart Federation
(WHF) criteria (Remenyi et al., 2012). Subjects were excluded from the
RHD negative controls if they had elevated anti-streptolysin O, borderline
RHDbyWHF criteria or had congenital heart disease or heart failure other
than fromRHD.Written informed consentwas obtained fromeachpartic-
ipant and the study was approved by the Institutional Review Boards at
University Hospitals, Cleveland, Ohio and Makerere University, Kampala,
Uganda.
HIV-1/2 testing was performed on all participants, unless an HIV di-
agnosis had previously been conﬁrmed with rapid antibody testing and
conﬁrmed by ELISA orWestern Blot. We used a primary rapid antibody
test (Alere Determine HIV-1/2) with conﬁrmation by Trinity Biotech
Uni-Gold and AccuBioTech tests. Patients whowere newly HIV positive
were also referred for further care and conﬁrmatory testing to the Joint
Clinical Research Centre or other preferred HIV treatment center. Ve-
nous blood was obtained by venipuncture and a complete blood
count, Anti-streptolysin O (ASO), and high sensitivity CRP (hsCRP)
were measured at the clinical laboratory of the Uganda Heart Institute.
CD4 count was measured in all HIV positive subjects. Serum samples
were frozen and stored at the Joint Clinical Research Centre at−80 °C
without thawing before autoantibody analysis. At the time of enroll-
ment clinical history was obtained by chart review. All data were stored
in a REDCap database hosted at University Hospitals, Cleveland (Harris
et al., 2009).
2.2. Natural Autoantibodies
Levels of anti-phosphorylcholine (PC) and anti-malondialdeyhyde
(MDA) antibodies were measured in duplicate from frozen serum sam-
ples by in-house assays, as previously described (Gronwall et al., 2012).
Herein, ELISA wells were coated with PC6-BSA (Biosearch Technologies
Inc., Novato, CA, USA) orMDA-BSA (Academic Bio-medical Co., Houston,
TX, USA). Values were reported from 1:1000 dilutions in 1% BSA-PBS
after detectionwith goat anti-IgM-HRP (Southern Biotech, Birmingham,
AL, USA) or goat anti-IgG-HRP (Jackson Immunosearch,West Grove, PA,
USA). An established standard curve from a SLE pool was used for cali-
bration. Assays for IgG anti-PC or IgM anti-MDA were not included as
pilot studies have shown these levels to be non-informative [data not
shown] (Gronwall et al., 2012).
2.3. Statistics
Baseline demographic and clinical characteristics were described
with standard descriptive statistics. Median natural autoantibody or in-
ﬂammatory marker levels were compared between groups using the
Kruskal–Wallis test. Linear regression was used to assess the effect of
HIV and RHD on autoantibody and inﬂammatory marker levels while
adjusting for age and sex and accounting for potential effect modiﬁca-
tion between HIV and RHD by testing their cross product term. The
linearity and normality of residuals assumptions were assessed with
residual by predicted plots and quantile–quantile plots respectively.
Violations were rectiﬁed by log-transforming the outcome variables.
P values less than 0.05 were considered signiﬁcant. SAS 9.3 was used
for statistical analyses (SAS Institute Inc., Cary, NC, USA).
2.4. Funding
The study was funded by the National Institutes of Health, American
College of Rheumatology, and Medtronic Philanthropy. No funding
source had any role in the design of the study.
3. Results
Overall, 231 participants were enrolled at the two Ugandan sites
(Fig. 1); however, eleven were later excluded from the RHD negative
control group because of an elevated ASO or an abnormal screening
Fig. 1. Total enrollment at the Uganda Heart Institute and Joint Clinical Research Centre.
Fig. 2.Median (IQR) levels of protective IgM anti-PC by RHD and HIV status.
163D.M. Huck et al. / EBioMedicine 5 (2016) 161–166echocardiogram. The baseline characteristics of the ﬁnal 220 study par-
ticipants are presented in Table 1. Age distribution was similar between
groups by design. CD4 counts and rates of ART use among HIV groups
were similar (p N 0.71). Participants with RHD (RHD+HIV− and
RHD+HIV+) had higher levels of hsCRP (p b 0.0001). The distribution
of aortic/mitral regurgitation and stenosis was similar among the two
RHD groups (p N 0.43).
The median anti-PC and anti-MDA levels by group, comparing each
disease group with the RHD−HIV− controls, are depicted in Figs. 2
and 3.We found that anti-PC IgMwas lower in both HIV+ groups com-
pared to the RHD−HIV− group, while for anti-MDA IgG there were no
signiﬁcant differences between the 3 disease groups and controls (all
p N 0.10). In further subgroup analysis of HIV positive individuals,
those with CD4 count b200 (n = 12) did not differ with respect toTable 1
Baseline characteristics of study participants.
Characteristics Total RHD−HIV−
Count 220 57
Age (years)a 33 (11) 33 (11)
Age range 10–60 15–60
Female 144 (65) 32 (56)
Baseline lab values
WBCb 4.8 (3.7–5.9) 4.8 (3.7–5.9)
Leukopenia (b4) 65 (30) 19 (33)
HGBb 13.9 (12.7–15.5) 14.5 (13.1–15.8)
Anemia (b12.1) 34 (15) 8 (14)
PLTb 241 (187–290) 242 (179–274)
Thrombocytopenia 21 (10) 7 (12)
ASOb 61 (38–96) 61 (43–82)
N200 6 (3) 0
hsCRPb 2.28 (0.67–5.72) 1.15 (0.47–2.95)
0–1 75 (34) 28 (49)
1–3 55 (25) 15 (26)
N3 89 (41) 14 (25)
RHD characteristics
Mitral or aortic disease rate
Mitral regurgitation N/A 0 (0)
Mitral stenosis N/A 0 (0)
Aortic regurgitation N/A 0 (0)
Aortic stenosis N/A 0 (0)
Ejection fraction b55% N/A 1 (2)
HIV characteristics
CD4b N/A N/A
Diagnosis CD4b N/A N/A
HIV diagnosis duration (years)b N/A N/A
On ART N/A N/A
ART duration (years)b N/A N/A
a Mean (SD).
b Median (IQR).anti-PC IgM when compared to those with a CD4 count N500 (n =
33) [median (Q25–Q75): 12 (8–40) U/mL vs. 19 (7–37) U/mL, p =
0·91]. Similarly, there was no difference in anti-MDA IgG [16 (7–
25) U/mL for CD4 b 200 vs. 11 (3–25) U/mL for CD4 N 500, p = 0.64].
To further explore the effect of HIV and RHD on autoantibody levels,
an adjusted analysis allowing for interaction was conducted (Table 2).
In these models, HIV infection and RHD were each independently asso-
ciated with lower anti-PC IgM (HIV: p b 0.0001 and RHD: p = 0.012).
There was no evidence of effect modiﬁcation interaction between RHDRHD+HIV+ RHD+HIV− RHD−HIV+
21 94 48
33 (11) 33 (11) 32 (12)
13–52 13–53 10–52
17 (81) 61 (65) 34 (71)
4.1 (3.7–4.9) 5.6 (4.5–6.6) 3.9 (3.1–4.7)
7 (33) 15 (16) 24 (50)
13.5 (12.5–15.1) 14.0 (12.6–15.8) 13.3 (12.3–14·4)
3 (14) 15 (16) 8 (17)
245 (218–287) 219 (179–281) 270 (219–353)
1 (5) 12 (13) 1 (2)
41 (20–125) 68 (45–104) 38 (22–67)
1 (0) 5 (5) 0
2.12 (0.80–4.09) 3.99 (1.64–12.37) 1.21 (0.43–4.62)
7 (33) 18 (19) 21 (44)
5 (24) 22 (23) 13 (27)
9 (43) 54 (57) 14 (29)
17 (81) 66 (70) 0 (0)
8 (38) 42 (45) 0 (0)
7 (33) 43 (46) 0 (0)
1 (5) 8 (8) 0 (0)
2 (10) 18 (19) 0 (0)
493 (364–816) N/A 536 (317–623)
237 (39–680) N/A 435 (137–648)
9 (4–11) N/A 6 (5–9)
19 (90) N/A 42 (88)
6 (2–10) N/A 6 (1–8)
Fig. 3.Median (IQR) levels of IgG anti-MDA by RHD and HIV status.
164 D.M. Huck et al. / EBioMedicine 5 (2016) 161–166and HIV (p = 0.50) for levels of anti-PC IgM, and thus it was removed
from the model. A signiﬁcant HIV*RHD interaction was identiﬁed for
IgG anti-MDA (p = 0.045) such that in participants without RHD we
found that HIV infection was associated with increased IgG anti-MDA,
whereas it was associated with decreased IgG anti-MDA in participants
with RHD.
4. Discussion
Our study demonstrates that HIV infection is associated with low
levels of IgM natural autoantibody to the oxidation-associated epi-
tope phosphorylcholine (PC), and high IgG natural autoantibody to
the distinct oxidation associated epitope, malondialdehyde (MDA).
Phosphorylcholine and malondialdehyde containing determinants
are both commonly expressed on apoptotic cells and on oxidized
LDL that is prevalent in atherosclerotic plaques. Studies in other con-
ditions have supported the notion that IgM natural autoantibodies to
PC can protect against autoimmune diseases and atherosclerosis,
whereas IgG anti-MDA antibodies are associated with more severe
autoimmune disease and higher risk of atherosclerotic cardiovascu-
lar disease.
These relationships between autoantibody responses and disease
have been well characterized in patients with SLE, the archetypic sys-
temic autoimmune disease (Gronwall et al., 2012); however, low IgM
anti-PC has also been associated with atherosclerosis and increased
risk of myocardial infarction and stroke in populations without known
autoimmune disease (Fiskesund et al., 2010; Gronlund et al., 2009). In
these latter studies, anti-PC IgM titer below the 30th percentile
corresponded with a multivariable adjusted relative risk of 1.62 (CITable 2
HIV and RHD are independently associated with low IgM anti-PC in multivariable linear
regression models of autoantibody levels.
Exposure
IgM anti-PCa IgG anti-MDAa
β P β P
Age (year) −0.005 0.12 −0.009 0.012
Female 0.074 0.31 −0.158 0.048
HIV+ −0.341 b0.0001 0.201 0.75
RHD+ −0.182 0.012 0.133 0.64
HIV+ RHD+ – – −0.347 0.045
a Log 10 transformed.1.11–2.35) for stroke, while a level below the 25th percentile was asso-
ciated with a relative risk of 1.69 (1.09–2.54) for myocardial infarction.
In our study, half of participants with HIV and over two-thirds of those
with both RHD and HIV had IgM anti-PC levels below the 25th percen-
tile of the RHD and HIV negative group (Supplementary Figs. 1 and 2),
suggesting that the degree to which these natural autoantibodies are
altered in HIV infection may also be associated with a clinically signiﬁ-
cant increase in myocardial infarction and stroke. While we did not
have statistical power to determine whether very low CD4 T-cell
count in HIV patients was associated with altered levels of autoanti-
bodies, given the associations in other cohorts between low nadir
and proximal CD4+ T-cells counts and cardiovascular events
(Longenecker and Triant, 2014), this should be further explored in
future studies.
Anti-MDA IgG has previously been associated with higher SLE
disease activity (Gronwall et al., 2012). In addition, higher MDA-LDL
levels in immune complexes have previously been associated with in-
creased rates ofmyocardial infarction (Lopes-Virella et al., 2012). Higher
levels of circulating IgG—especially the proinﬂammatory IgG1 and IgG3
subclasses that activate Fcγ receptors and complement—against
oxidation-associated epitopes (on LDL or other macromolecules) may
occur in the context of a higher burden of inﬂammatory atheroscle-
rotic plaque (Mironova et al., 1996). Indeed we observed higher
IgG against MDA in individuals with HIV, which we postulate may
correspond to increased inﬂammation and formation of oxidation
byproducts in these patients.
Although these speciﬁc types of natural autoantibodies that were
the focus of our investigations have not been previously studied in the
context of HIV, in a recent study, levels of anti-MDA-LDL antibodies
were evaluated in HIV-infected and uninfected subjects. It found
lower levels of IgM natural autoantibody against MDA-LDL and higher
levels of IgG againstMDA-LDL, although furthermolecular characteriza-
tions were not performed (Yilmaz et al., 2014). Another study of IgG
antibodies to oxidized LDL in HIV patients found a decrease in the levels
of these antibodies after immune reconstitution following initiation of
antiretroviral therapy (Ronchini et al., 2013). Our ﬁndings are therefore
similar to patterns previously reported in HIV infected subjects.
We found evidence of similar alterations in levels of certain natural
autoantibodies (low IgM anti-PC and high IgG anti-MDA) among
patients with RHD, although the effect size was smaller than for HIV in-
fection. As an autoimmune condition, RHDmay be associatedwith glob-
al immune dysregulation that also affects levels of these natural
autoantibodies, and further study with larger sample sizes are needed
to more clearly reveal this association. For the reasons mentioned
above, these ﬁndings may also provide insight into atherosclerotic vas-
cular disease risk in patients with RHD. Compared to classical athero-
sclerotic cardiovascular disease, patients with RHD tend to be younger
and their cardiovascular morbidity and mortality are driven more by
complications of progressive valvular heart failure and the need for
heart valve surgery. However, a national database study from Sweden
reported that hospitalization for acute rheumatic fever was associated
with a 4.7-fold increased risk of subsequent coronary heart disease
(Zoller et al., 2012). While intriguing, this ﬁnding could potentially be
confounded by ascertainment bias (i.e. RHD patients undergoing heart
valve surgery are routinely evaluated for co-existing coronary artery
disease). Another study found that carotid intima-media thickness and
aortic stiffness were increased in children with a prior diagnosis of
rheumatic fever (Ciftel et al., 2014). Therefore the relationships
between natural autoantibodies to oxidation-associated antigens,
subclinical vascular disease, ventricular-vascular interactions, and
RHD disease susceptibility and progression should be evaluated in
future studies.
A central aim of our study was to examine the interaction between
RHD and HIV status—two highly prevalent diseases in sub-Saharan
Africa. Very little is known about this interaction, although there is a
reason to believe that concurrent HIV infection may alter susceptibility
165D.M. Huck et al. / EBioMedicine 5 (2016) 161–166to RHD or RHD disease progression in positive and negative ways
(Longenecker et al., 2014). Our group has previously reported a de-
creased prevalence of latent rheumatic heart disease detected by echo-
cardiography amongHIV-infected children compared to other Ugandan
school children (Gleason et al., 2014) but there are many health system
factors (e.g. access to healthcare services, use of prophylactic antibi-
otics) thatmay confound thisﬁnding. Besides the ﬁnding that HIV infec-
tion may adversely affect the natural autoantibody responses, other
ﬁndings from our study suggest that HIV-infected patients with RHD
may be different from HIV-uninfected patients with RHD in ways that
may protect against RHDprogression. First, therewas an interaction be-
tween RHD and HIV in ourmultivariable model, such that HIV infection
was associated with lower anti-MDA IgG levels among subjects with
RHD—this is opposite of the effect of HIV in the overall cohort. Second,
HIV-infected subjects with and without RHD had lower ASO titers
thanHIV-uninfected controls. Thismay reﬂect a decreased burden of in-
vasive GAS infection among subjects with HIV, possibly due to better
engagement in care and access to antibiotics. Compared to uninfected
subjects with RHD, HIV-infected subjects with RHD had lower levels of
systemic inﬂammation as measured by hsCRP, again suggesting some
protective confounder.
Among the ﬁrst reported immune abnormality in HIV infected indi-
viduals was the appearance of rheumatoid factors and anti-nuclear an-
tibodies (Lane et al., 1985), and HIV infection also has been reported to
impact risk for some autoimmune diseases (Zandman-Goddard and
Shoenfeld, 2002). The immunosuppression caused by HIV at low
CD4+ T-cell counts may protect against autoimmune disease; in fact,
patients with SLE have been reported to symptomatically improve as
HIV disease progresses and CD4 counts declines, but then may later
symptomatically worsen after immune reconstitution with ART
(Zandman-Goddard and Shoenfeld, 2002). In the era of effective ART,
autoimmune disease may occur as an immune reconstitution in-
ﬂammatory syndrome (IRIS), but overall the incidence of associated
connective tissue diseases appears to be on the decline (Calabrese
et al., 2005; Iordache et al., 2014). In our study, HIV infectionwas as-
sociated with perturbations in levels of natural autoantibodies to
oxidation-associated determinants that have been previously asso-
ciated with increased disease severity in SLE (Gronwall et al., 2012).
HIV infection likely has a complex relationship with autoimmune
predisposition to diseases such as SLE and to RHD — perturbations
in these types of natural autoantibodies may also increase risk and
disease severity while the immunosuppression and profound CD4
T cell depletion in untreated HIV may reduce risk and disease
severity.
Our study has limitations. As with all cross-sectional studies, ours
cannot prove causal relationships or account for all potential con-
founders. Furthermore, our study may have been underpowered to de-
tect a signiﬁcant effect of CD4 count on natural autoantibodies. Because
our study was limited to Ugandans, our ﬁndings may not be applicable
to other populations that also have a high prevalence of both HIV and
RHD. Our study included patients with chronic RHD, but it would also
be useful to study subjects with acute rheumatic fever. Future studies
should also assess acquired autoantibodies that have been implicated
in RHD pathogenesis, including antibodies against myosin, collagen,
laminin, and other streptococcal proteins.
In conclusion, HIV infection appears to alter natural antibody levels
in ways that may increase risk of atherosclerosis and may impact the
pathogenesis of RHD. To our knowledge, there has been no prior
study that has characterized these clinical and immune characteristics
of HIV-infected patients with RHD, two immune disorders that are
highly prevalent in sub-Saharan Africa. Both RHD and HIV appear
to be associated with altered levels of circulating natural autoanti-
body to oxidation-associated determinants and therefore our ﬁnd-
ings suggest that there may be important interrelationships
between these two clinical conditions. These ﬁndings may therefore
have important implications for the study of autoimmunity as acontributing mechanism for cardiovascular disease in sub-Saharan
Africa and in areas of high HIV-prevalence worldwide.
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